Figure 8

FRAP analysis of 2 (BRS), ASC, 1 (BV) and BRDT (0–100 µM; n = 3) in both aqueous (left) and serum (right). Aqueous 2 reduces 3.819 molar equivalents of Fe³⁺-TPTZ, while ASC reduces 1.963 molar equivalents. In serum, 2 only reduces 3.069 molar equivalents while there is little difference between aqueous ASC and serum ASC (1.963 vs 1.991 molar equivalents, respectively). Related tetrapyrroles (1 and BRDT) both had more reductive potential than 2 (p < 0.05) in serum, however there was no significant difference in the reductive potential between aqueous 1 and 2. One way ANOVA and Fisher’s LSD was used to make multiple comparisons, p < 0.05 was considered significant.